Supply Chain

A review of COVID-19 vaccine access inequities, emerging cardioprotective data for semaglutide, and Experity’s integration with Amazon Pharmacy highlights the shifting dynamics of patient access, clinical innovation, and digital-first care delivery in today’s Pharma Pulse.

A new partnership integrates Amazon Pharmacy into Experity’s urgent care platform, enabling in-clinic prescription ordering, faster fulfillment, and improved treatment adherence through streamlined digital workflows.

The nationally licensed pharmacy network now supports Ethereum, Solana, and XRP across all retail locations, marking a major step toward faster, more transparent payments—and laying the groundwork for a blockchain-based prescription drug payment system.

The pharma giant’s new 10,000-square-foot Carlsbad plant strengthens its US manufacturing network and supports its overarching $50 billion investment plan committed to operations.

The deal—with the potential to be valued at up to $725 million—positions ThermoSafe for accelerated growth and innovation in temperature-controlled packaging solutions, with Arsenal aiming to expand global reach and technological capabilities.

The addition of Starjemza reinforces Mark Cuban Cost Plus Drugs' effort to expand access to affordable specialty medicines through its transparent cost-plus pricing model, while also enhancing patient support via a new partnership with Medchat.ai.

Cencora's investment includes new automated centers in Ohio and California and a major cold chain expansion in Alabama to enhance capacity, efficiency, and supply chain resilience.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

The investment is aimed at boosting oral medicine manufacturing capacity.

The move adds new tension to US-Canada trade relations under the USMCA and raises questions about pending pharmaceutical import policies.

The CDMO’s latest investment will boost capacity at its Charles City, IA facility by 40%, underscoring Cambrex’s focus on reshoring drug manufacturing, advancing peptide and small molecule production, and supporting the long-term stability of the US pharma supply chain.

The acquisition brings together two leaders in mRNA innovation, strengthening BioNTech’s oncology strategy and expanding its R&D and commercialization capabilities.

The new partnership aims to transform cold chain logistics for life sciences, creating a connected air transport network designed to ensure temperature integrity, regulatory compliance, and faster delivery of critical therapies.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, shares that as DSCSA traceability requirements take full effect, distributors and trading partners are preparing for long-term gains in supply chain security, recall efficiency, and counterfeit prevention.

The company’s new 400,000-square-foot facility in Elkton will boost small molecule manufacturing, create hundreds of jobs, and strengthen US innovation and supply chain resilience.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, describes how FDA officials are signaling a balanced enforcement approach when it comes to DSCSA enforcement, expecting compliance efforts and documentation, but also recognizing that perfection will take time.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, details that after a year of steady progress, manufacturers and distributors report over 97% data accuracy under DSCSA traceability requirements, marking a major milestone in supply chain interoperability and signaling confidence ahead of the November compliance deadline.

The collaboration demonstrates that ocean freight can safely transport temperature-sensitive medicines, offering the pharma industry a cost-effective, sustainable alternative to air cargo.

The $445 million expansion of AstraZeneca’s Coppelsite will boost global production capacity for Lokelma, enhance local job growth, and strengthen the company’s US manufacturing footprint amid industry-wide onshoring trends.

A planned 100% tariff on branded and patented drugs from Singapore is being postponed as US and Singapore officials explore potential exemptions.

The fallout is impacting partners Scholar Rock and Regeneron, both of whom have pending regulatory applications tied to the facility.

Krenar Komoni, founder and CEO of Tive, predicts that AI-driven automation and its accelerating impact on pharmaceutical supply chains will remain a headline topic at LogiPharma USA, as the industry faces growing pressure to innovate while balancing strict regulatory requirements.

This episode of Pharma Pulse covers how recent CDC layoffs are fueling concerns about disease surveillance, Ypsomed’s new autoinjector manufacturing site in North Carolina, and Lupin’s $250 million investment to build a respiratory and specialty drug facility in Florida.

The global generics maker’s new Florida site will produce more than 25 critical respiratory medicines, create over 200 jobs, and reinforce domestic manufacturing and drug security.

Krenar Komoni, founder and CEO of Tive, highlights the transition in pharma from passive to real-time temperature control, noting delays in technology adoption but emphasizing how AI and automation will soon drive cost savings, improved quality, and stronger customer experience.